ヘモグロビン異常症の世界市場規模、シェア、産業動向分析レポート：タイプ別、流通チャネル別、治療法別、地域別展望と予測、2022年～2028年

ヘモグロビン異常症の世界市場規模は、2028年には60億米ドルに達し、予測期間中にCAGR5.6%の市場成長率で上昇すると予測されています。

例えば、赤血球を変形または損傷させる不安定なヘモグロビンに起因するそのような血液疾患の1つは、鎌状赤血球症（SCD）と呼ばれています。赤血球の異常な破壊は貧血を引き起こし、血管を詰まらせ、多臓器虚血障害や急性疼痛を引き起こします。特に西半球（中米、カリブ海、南米）、サハラ以南のアフリカ、インド、サウジアラビア、ギリシャ、イタリア、トルコなどの地中海沿岸諸国を祖先とする数百万人の人々がSCDに罹患しています。

鎌状赤血球症の治療には、骨髄移植や血液幹細胞移植が行われます。SCDの臨床的な強さは様々で、時には気づかないような軽度の問題から、緊急の入院が必要な重篤な影響まであります。対症療法として薬物療法があります。また、新生児スクリーニング（NBS）により、SCDを発見し、子供や新生児への影響を軽減することができます。

COVID-19の影響分析

COVID-19の大流行は、ほぼすべての産業に影響を与えています。ヘモグロビン異常症市場やその他多くの分野、特に健康・医薬品分野の大幅な落ち込みにより、医療機関はCOVID-19対策に資金と時間の大半を集中させなければならない状況になりました。ヘモグロビン症患者の治療の中断は、主に病院での感染症のリスクによるものでした。ヘモグロビン症の患者さんには、特別な健康管理が必要です。いくつかの医薬品や治療法に対する需要は、パンデミックの間に著しく増加しました。それでも、工場の操業停止などの制限により、生産は必要なニーズを満たすことができませんでした。

市場の成長要因

低開発国におけるヘモグロビン症の症例の増加

遺伝性ヘモグロビン疾患の正確な患者数についてはデータが限られていますが、医療資源にとって大きな負担となることは間違いありません。低開発国の公的ヘルスケアシステムも改善されつつあり、それに伴い、これらの病気に苦しむ子どもたちの生存率も上がってきているので、後の治療のために利用できる患者さんが増えるということです。遺伝性ヘモグロビン異常症は、単発性疾患の中で最も多い疾患とされています。

研究開発への高い投資額

組織指向で安全かつ効率的な遺伝子編集技術の成長が、ヘモグロビン関連疾患に対するさまざまな遺伝子治療の開発に寄与しています。遺伝子治療は患者さんを治療できる可能性を秘めています。新しい有望な治療法の登場により、治療費全体がより安価になることが期待されます。現在、βラミノパチーにおけるヘモグロビン産生を救済するために、これらの遺伝子編集・付加技術の効率性と安全性を見出すための試験が増加しています。

市場抑制要因

臨床試験の失敗と治療における高いリスク

鎌状赤血球症は、現在、造血幹細胞移植が唯一の治療法となっています。この方法は、その適応と管理に関する診療ガイドラインが作られるほど進化しています。しかし、数多くのプロトコールがあるにもかかわらず、それらで治療を受けている患者さんの数はわずかです。さらに、移植された鎌状赤血球患者における固形がんの長期的な副作用も懸念される分野です。医療分野では日進月歩の進歩がありますが、ヘモグロビン症の病気に対する恒久的な治療法はまだ確立されていないのが現状です。

タイプ別の展望

ヘモグロビン症市場は、タイプ別に、サラセミア、鎌状赤血球症、その他に分類されます。サラセミアセグメントは、2021年のヘモグロビン症市場において最も高い収益シェアを獲得しました。これは、サラセミアは遺伝子の変化により引き起こされる血液疾患の一種であるためです。サラセミアには、主に2つのタイプがあります。1つは、αグロビンタンパク質遺伝子または遺伝子が欠損または変異している場合に起こるαサラセミアです。もう1つは、βグロビン蛋白の産生が変化することで発症するβサラセミアです。

販売チャネル

販売チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア、小売薬局に分類されます。2021年のヘモグロビン異常症市場では、病院薬局部門が大きな収益シェアを記録しました。診療、調剤、配合、保管、医薬品・医療機器の調剤、患者カウンセリングなどのヘルスケアサービスの構成があるためです。また、効果的、安全、効率的に使用するために、医師や看護師などのヘルスケア専門家がいます。医療施設では、患者の健康管理の一端を担う薬学の専門分野として、病院薬剤師があります。

治療法の展望

ヘモグロビン異常症市場は、治療法別にモノクローナル抗体医薬、ACE阻害剤、ヒドロキシ尿素、その他に分類されます。2021年のヘモグロビン症市場では、Monoclonal Antibody Medication分野が最大の収益シェアを獲得しました。これは、治療に十分な薬剤が利用できることと、サラセミア患者がモノクローナル抗体投薬によって健康的な回復を示すためです。モノクローナル抗体は、人間の体が作る抗体に似ており、免疫系の活動を模倣しています。血液から特定の抗体を抽出し、クローン化することで作られます。

地域別の展望

地域別に見ると、ヘモグロビン異常症市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2021年にヘモグロビンオパチー市場で最大の収益シェアを獲得しました。ヘモグロビン症に関連する疾患や、その治療のための新しい治療法を研究・発見する必要性についての認識を広めるために、さまざまな組織が開始した啓発プログラムによるものです。また、この病気が広く発見されている地域からの移民の増加や、新しく強化された治療薬の入手が可能であることも、市場の成長を促進すると予想されます。

目次

第1章 市場の範囲と調査手法

• 市場の定義
• 目的
• 市場規模
• セグメンテーション
  • ヘモグロビン異常症の世界市場、タイプ別
  • ヘモグロビン異常症の世界市場：流通経路別
  • ヘモグロビン異常症の世界市場：治療法別
  • ヘモグロビン異常症の世界市場：地域別
• 調査手法

第2章 市場概要

• イントロダクション
  • 概要の説明
    • 市場の構成とシナリオ
• 市場に影響を与える主な要因
  • 市場促進要因
  • 市場の抑制要因

第3章 ヘモグロビン異常症の世界市場：タイプ別

• サラセミアの世界市場：地域別
• 鎌状赤血球症の世界市場：地域別
• その他の世界市場：地域別

第4章 ヘモグロビン異常症の世界市場流通チャネル別

• ドラッグストア・小売薬局の世界市場：地域別
• 病院内薬局の世界市場：地域別
• オンラインプロバイダーの世界市場：地域別

第5章 ヘモグロビン異常症の世界市場治療法別

• モノクローナル抗体製剤の世界市場：地域別
• ヒドロキシ尿素の世界市場：地域別
• ACE阻害剤の世界市場：地域別
• その他の世界市場：地域別

第6章 ヘモグロビン異常症の世界市場：地域別

• 北米
  • 北米のヘモグロビン異常症の国別市場
    • 米国
    • カナダ
    • メキシコ
    • その他北米地域
• 欧州
  • 欧州のヘモグロビン異常症国別市場
    • ドイツ
    • 英国
    • フランス
    • ロシア
    • スペイン
    • イタリア
    • その他欧州
• アジア太平洋地域
  • アジア太平洋地域のヘモグロビン異常症国別市場
    • 中国
    • 日本
    • インド
    • 韓国
    • シンガポール
    • マレーシア
    • その他アジア太平洋地域
• LAMEA
  • LAMEAのヘモグロビン異常症市場：国別
    • ブラジル
    • アルゼンチン
    • UAE
    • サウジアラビア
    • 南アフリカ共和国
    • ナイジェリア
    • その他のLAMEA

第7章 企業プロファイル

• Abbott Laboratories
• Sanofi S.A
• Danaher Corporation
• Pfizer, Inc.（Global Blood Therapeutics, Inc.）
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Alnylam Pharmaceuticals, Inc.
• Emmaus Life Sciences, Inc.
• Biogen, Inc.
• Canthera Discovery Ltd.

LIST OF TABLES

• TABLE 1 Global Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 2 Global Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 3 Global Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 4 Global Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 5 Global Thalassemia Market by Region, 2018 - 2021, USD Million
• TABLE 6 Global Thalassemia Market by Region, 2022 - 2028, USD Million
• TABLE 7 Global Sickle Cell Disease Market by Region, 2018 - 2021, USD Million
• TABLE 8 Global Sickle Cell Disease Market by Region, 2022 - 2028, USD Million
• TABLE 9 Global Others Market by Region, 2018 - 2021, USD Million
• TABLE 10 Global Others Market by Region, 2022 - 2028, USD Million
• TABLE 11 Global Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 12 Global Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 13 Global Drug Stores & Retail Pharmacy Market by Region, 2018 - 2021, USD Million
• TABLE 14 Global Drug Stores & Retail Pharmacy Market by Region, 2022 - 2028, USD Million
• TABLE 15 Global Hospital Pharmacy Market by Region, 2018 - 2021, USD Million
• TABLE 16 Global Hospital Pharmacy Market by Region, 2022 - 2028, USD Million
• TABLE 17 Global Online Providers Market by Region, 2018 - 2021, USD Million
• TABLE 18 Global Online Providers Market by Region, 2022 - 2028, USD Million
• TABLE 19 Global Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 20 Global Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 21 Global Monoclonal Antibody Medication Market by Region, 2018 - 2021, USD Million
• TABLE 22 Global Monoclonal Antibody Medication Market by Region, 2022 - 2028, USD Million
• TABLE 23 Global Hydroxyurea Market by Region, 2018 - 2021, USD Million
• TABLE 24 Global Hydroxyurea Market by Region, 2022 - 2028, USD Million
• TABLE 25 Global ACE Inhibitors Market by Region, 2018 - 2021, USD Million
• TABLE 26 Global ACE Inhibitors Market by Region, 2022 - 2028, USD Million
• TABLE 27 Global Others Market by Region, 2018 - 2021, USD Million
• TABLE 28 Global Others Market by Region, 2022 - 2028, USD Million
• TABLE 29 Global Hemoglobinopathies Market by Region, 2018 - 2021, USD Million
• TABLE 30 Global Hemoglobinopathies Market by Region, 2022 - 2028, USD Million
• TABLE 31 North America Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 32 North America Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 33 North America Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 34 North America Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 35 North America Thalassemia Market by Country, 2018 - 2021, USD Million
• TABLE 36 North America Thalassemia Market by Country, 2022 - 2028, USD Million
• TABLE 37 North America Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
• TABLE 38 North America Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
• TABLE 39 North America Others Market by Country, 2018 - 2021, USD Million
• TABLE 40 North America Others Market by Country, 2022 - 2028, USD Million
• TABLE 41 North America Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 42 North America Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 43 North America Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 44 North America Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 45 North America Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 46 North America Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 47 North America Online Providers Market by Country, 2018 - 2021, USD Million
• TABLE 48 North America Online Providers Market by Country, 2022 - 2028, USD Million
• TABLE 49 North America Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 50 North America Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 51 North America Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
• TABLE 52 North America Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
• TABLE 53 North America Hydroxyurea Market by Country, 2018 - 2021, USD Million
• TABLE 54 North America Hydroxyurea Market by Country, 2022 - 2028, USD Million
• TABLE 55 North America ACE Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 56 North America ACE Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 57 North America Others Market by Country, 2018 - 2021, USD Million
• TABLE 58 North America Others Market by Country, 2022 - 2028, USD Million
• TABLE 59 North America Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
• TABLE 60 North America Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
• TABLE 61 US Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 62 US Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 63 US Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 64 US Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 65 US Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 66 US Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 67 US Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 68 US Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 69 Canada Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 70 Canada Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 71 Canada Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 72 Canada Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 73 Canada Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 74 Canada Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 75 Canada Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 76 Canada Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 77 Mexico Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 78 Mexico Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 79 Mexico Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 80 Mexico Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 81 Mexico Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 82 Mexico Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 83 Mexico Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 84 Mexico Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 85 Rest of North America Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 86 Rest of North America Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 87 Rest of North America Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 88 Rest of North America Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 89 Rest of North America Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 90 Rest of North America Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 91 Rest of North America Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 92 Rest of North America Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 93 Europe Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 94 Europe Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 95 Europe Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 96 Europe Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 97 Europe Thalassemia Market by Country, 2018 - 2021, USD Million
• TABLE 98 Europe Thalassemia Market by Country, 2022 - 2028, USD Million
• TABLE 99 Europe Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
• TABLE 100 Europe Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
• TABLE 101 Europe Others Market by Country, 2018 - 2021, USD Million
• TABLE 102 Europe Others Market by Country, 2022 - 2028, USD Million
• TABLE 103 Europe Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 104 Europe Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 105 Europe Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 106 Europe Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 107 Europe Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 108 Europe Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 109 Europe Online Providers Market by Country, 2018 - 2021, USD Million
• TABLE 110 Europe Online Providers Market by Country, 2022 - 2028, USD Million
• TABLE 111 Europe Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 112 Europe Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 113 Europe Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
• TABLE 114 Europe Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
• TABLE 115 Europe Hydroxyurea Market by Country, 2018 - 2021, USD Million
• TABLE 116 Europe Hydroxyurea Market by Country, 2022 - 2028, USD Million
• TABLE 117 Europe ACE Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 118 Europe ACE Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 119 Europe Others Market by Country, 2018 - 2021, USD Million
• TABLE 120 Europe Others Market by Country, 2022 - 2028, USD Million
• TABLE 121 Europe Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
• TABLE 122 Europe Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
• TABLE 123 Germany Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 124 Germany Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 125 Germany Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 126 Germany Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 127 Germany Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 128 Germany Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 129 Germany Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 130 Germany Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 131 UK Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 132 UK Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 133 UK Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 134 UK Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 135 UK Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 136 UK Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 137 UK Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 138 UK Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 139 France Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 140 France Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 141 France Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 142 France Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 143 France Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 144 France Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 145 France Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 146 France Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 147 Russia Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 148 Russia Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 149 Russia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 150 Russia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 151 Russia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 152 Russia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 153 Russia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 154 Russia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 155 Spain Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 156 Spain Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 157 Spain Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 158 Spain Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 159 Spain Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 160 Spain Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 161 Spain Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 162 Spain Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 163 Italy Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 164 Italy Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 165 Italy Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 166 Italy Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 167 Italy Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 168 Italy Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 169 Italy Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 170 Italy Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 171 Rest of Europe Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 172 Rest of Europe Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 173 Rest of Europe Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 174 Rest of Europe Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 175 Rest of Europe Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 176 Rest of Europe Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 177 Rest of Europe Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 178 Rest of Europe Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 179 Asia Pacific Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 180 Asia Pacific Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 181 Asia Pacific Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 182 Asia Pacific Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 183 Asia Pacific Thalassemia Market by Country, 2018 - 2021, USD Million
• TABLE 184 Asia Pacific Thalassemia Market by Country, 2022 - 2028, USD Million
• TABLE 185 Asia Pacific Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
• TABLE 186 Asia Pacific Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
• TABLE 187 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
• TABLE 188 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
• TABLE 189 Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 190 Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 191 Asia Pacific Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 192 Asia Pacific Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 193 Asia Pacific Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 194 Asia Pacific Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 195 Asia Pacific Online Providers Market by Country, 2018 - 2021, USD Million
• TABLE 196 Asia Pacific Online Providers Market by Country, 2022 - 2028, USD Million
• TABLE 197 Asia Pacific Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 198 Asia Pacific Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 199 Asia Pacific Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
• TABLE 200 Asia Pacific Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
• TABLE 201 Asia Pacific Hydroxyurea Market by Country, 2018 - 2021, USD Million
• TABLE 202 Asia Pacific Hydroxyurea Market by Country, 2022 - 2028, USD Million
• TABLE 203 Asia Pacific ACE Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 204 Asia Pacific ACE Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 205 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
• TABLE 206 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
• TABLE 207 Asia Pacific Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
• TABLE 208 Asia Pacific Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
• TABLE 209 China Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 210 China Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 211 China Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 212 China Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 213 China Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 214 China Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 215 China Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 216 China Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 217 Japan Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 218 Japan Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 219 Japan Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 220 Japan Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 221 Japan Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 222 Japan Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 223 Japan Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 224 Japan Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 225 India Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 226 India Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 227 India Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 228 India Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 229 India Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 230 India Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 231 India Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 232 India Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 233 South Korea Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 234 South Korea Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 235 South Korea Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 236 South Korea Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 237 South Korea Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 238 South Korea Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 239 South Korea Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 240 South Korea Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 241 Singapore Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 242 Singapore Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 243 Singapore Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 244 Singapore Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 245 Singapore Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 246 Singapore Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 247 Singapore Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 248 Singapore Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 249 Malaysia Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 250 Malaysia Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 251 Malaysia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 252 Malaysia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 253 Malaysia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 254 Malaysia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 255 Malaysia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 256 Malaysia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 257 Rest of Asia Pacific Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 258 Rest of Asia Pacific Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 259 Rest of Asia Pacific Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 260 Rest of Asia Pacific Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 261 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 262 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 263 Rest of Asia Pacific Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 264 Rest of Asia Pacific Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 265 LAMEA Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 266 LAMEA Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 267 LAMEA Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 268 LAMEA Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 269 LAMEA Thalassemia Market by Country, 2018 - 2021, USD Million
• TABLE 270 LAMEA Thalassemia Market by Country, 2022 - 2028, USD Million
• TABLE 271 LAMEA Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
• TABLE 272 LAMEA Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
• TABLE 273 LAMEA Others Market by Country, 2018 - 2021, USD Million
• TABLE 274 LAMEA Others Market by Country, 2022 - 2028, USD Million
• TABLE 275 LAMEA Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 276 LAMEA Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 277 LAMEA Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 278 LAMEA Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 279 LAMEA Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
• TABLE 280 LAMEA Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
• TABLE 281 LAMEA Online Providers Market by Country, 2018 - 2021, USD Million
• TABLE 282 LAMEA Online Providers Market by Country, 2022 - 2028, USD Million
• TABLE 283 LAMEA Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 284 LAMEA Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 285 LAMEA Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
• TABLE 286 LAMEA Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
• TABLE 287 LAMEA Hydroxyurea Market by Country, 2018 - 2021, USD Million
• TABLE 288 LAMEA Hydroxyurea Market by Country, 2022 - 2028, USD Million
• TABLE 289 LAMEA ACE Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 290 LAMEA ACE Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 291 LAMEA Others Market by Country, 2018 - 2021, USD Million
• TABLE 292 LAMEA Others Market by Country, 2022 - 2028, USD Million
• TABLE 293 LAMEA Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
• TABLE 294 LAMEA Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
• TABLE 295 Brazil Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 296 Brazil Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 297 Brazil Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 298 Brazil Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 299 Brazil Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 300 Brazil Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 301 Brazil Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 302 Brazil Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 303 Argentina Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 304 Argentina Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 305 Argentina Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 306 Argentina Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 307 Argentina Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 308 Argentina Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 309 Argentina Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 310 Argentina Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 311 UAE Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 312 UAE Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 313 UAE Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 314 UAE Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 315 UAE Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 316 UAE Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 317 UAE Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 318 UAE Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million

• TABLE 319 Saudi Arabia Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 320 Saudi Arabia Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 321 Saudi Arabia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 322 Saudi Arabia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 323 Saudi Arabia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 324 Saudi Arabia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 325 Saudi Arabia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 326 Saudi Arabia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 327 South Africa Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 328 South Africa Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 329 South Africa Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 330 South Africa Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 331 South Africa Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 332 South Africa Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 333 South Africa Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 334 South Africa Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 335 Nigeria Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 336 Nigeria Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 337 Nigeria Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 338 Nigeria Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 339 Nigeria Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 340 Nigeria Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 341 Nigeria Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 342 Nigeria Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 343 Rest of LAMEA Hemoglobinopathies Market, 2018 - 2021, USD Million
• TABLE 344 Rest of LAMEA Hemoglobinopathies Market, 2022 - 2028, USD Million
• TABLE 345 Rest of LAMEA Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
• TABLE 346 Rest of LAMEA Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
• TABLE 347 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
• TABLE 348 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
• TABLE 349 Rest of LAMEA Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
• TABLE 350 Rest of LAMEA Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
• TABLE 351 Key Information - Abbott Laboratories
• TABLE 352 Key Information - Sanofi S.A.
• TABLE 353 Key Information - Danaher Corporation
• TABLE 354 Key Information - Pfizer, Inc.
• TABLE 355 KEY INFORMATION - Merck & Co., Inc.
• TABLE 356 Key Information - Bristol Myers Squibb Company
• TABLE 357 Key Information - Alnylam Pharmaceuticals, Inc.
• TABLE 358 Key Information - Emmaus Life Sciences, INC.
• TABLE 359 Key Information - Biogen, Inc.
• TABLE 360 Key Information - Canthera Discovery Ltd.

List of Figures

• FIG 1 Methodology for the research
• FIG 2 Global Hemoglobinopathies Market Share by Type, 2021
• FIG 3 Global Hemoglobinopathies Market Share by Type, 2028
• FIG 4 Global Hemoglobinopathies Market by Type, 2018 - 2028, USD Million
• FIG 5 Global Hemoglobinopathies Market Share by Distribution Channel, 2021
• FIG 6 Global Hemoglobinopathies Market Share by Distribution Channel, 2028
• FIG 7 Global Hemoglobinopathies Market by Distribution Channel, 2018 - 2028, USD Million
• FIG 8 Global Hemoglobinopathies Market Share by Therapy, 2021
• FIG 9 Global Hemoglobinopathies Market Share by Therapy, 2028
• FIG 10 Global Hemoglobinopathies Market by Therapy, 2018 - 2028, USD Million
• FIG 11 Global Hemoglobinopathies Market Share by Region, 2021
• FIG 12 Global Hemoglobinopathies Market Share by Region, 2028
• FIG 13 Global Hemoglobinopathies Market by Region, 2018 - 2028, USD Million
• FIG 14 Swot analysis: Abbott laboratories

The Global Hemoglobinopathies Market size is expected to reach $6.0 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.

In its stable state, normal human hemoglobin's are tetrameric protein composed of two globin chains, each of which has an alpha (α-like) chain and a beta (B-like) chain. Every globin chain is attached to a heme moiety that contains iron. The synthesis of alpha-like and beta-like (also known as non-alpha-like) is maintained throughout the lifetime, so their ratio remains constant. In the human body, hemoglobin is used to transport oxygen from the lungs to tissues.

This happens as the globin chains enable the molecules to take up more oxygen in places with high oxygen concentrations and release oxygen in areas with low oxygen concentrations. Hemoglobin also transports carbon dioxide and nitric oxides. Hemoglobinopathies are a set of hereditary diseases. In these diseases, there is an abnormal synthesis or structure of the hemoglobin molecules.

For example, one such blood condition caused due to unstable hemoglobin that deforms or damages the red blood cells is called sickle cell disease (SCD). The unusual red blood cell breakdown causes anemia and clogs the blood vessels, leading to multi-organ ischemic damage and acute pain. Millions of individuals are affected by SCD, especially those whose ancestral origin is from Western Hemisphere (Central America, Caribbean, and South America), Sub-Saharan Africa, India, Saudi Arabia, and Mediterranean counties like Greece, Italy, and Turkey.

Bone marrow transplants and blood stem cells are used to treat Children with sickle cell disease. The clinical intensity of SCD varies, ranging from minor problems that sometimes go unnoticed to severe effects that need urgent hospitalization. There are medications for symptomatic effects. Also, newborn screening (NBS) can help discover SCD to lessen some of the disease's impact on children and newborns.

COVID - 19 Impact Analysis

The COVID-19 pandemic has affected nearly all industries; it has forced healthcare organizations to concentrate the majority of funds and time on fighting COVID-19, due to a significant drop in the hemoglobinopathies market and many other sectors, especially in health and pharmaceutical, was reported. The interruptions in treating hemoglobinopathy patients were primarily due to the risk of infection in the hospitals. Special health needs are required for patients with hemoglobinopathy. The demand for several drugs and treatments has significantly increased during the pandemic. Still, due to the shutdown of factories and other restrictions, production was unable to meet the required needs.

Market Growth Factors

The rising cases of hemoglobinopathy in under-developed countries

There is a limitation in data related to the exact number of inherited hemoglobin illnesses, but still, they are certainly going to be a major burden for healthcare resources. The public healthcare system in under-developed countries is also improving, and with that, the survival rate of children suffering from these diseases is also increasing, which means more patients will be available for later treatments. Inherited hemoglobin disorder is considered to be the most common monogenic illness.

High investments in research and development

The growth of tissue-oriented, safe, and efficient gene editing technology has contributed to the development of various gene therapy types for hemoglobin-related illnesses. Gene therapy has the potential to treat patients. As new and promising therapeutic options appear, the overall cost of treatment is expected to get more affordable. Presently, an increasing number of trials to find the efficiency and safety of these gene editing and addition technologies to rescue hemoglobin production in beta laminopathies are going on.

Market Restraining Factors

Failure of the clinical trials and high risk in treatment

A hematopoietic stem cell transplant is currently the only available treatment for Sickle Cell Disease. This approach has evolved enough to have resulted in practice guidelines for its indication and management. But despite the numerous protocols, the number of patients treated with them is only a few. Moreover, the long-term side effects of solid tumors in transplanted Sickle cell patients are also an area of concern. Although there is constant advancement in the medical sector, there is still a lack of permanent treatment for hemoglobinopathy illness.

Type Outlook

Based on the Type, the Hemoglobinopathy Market is segmented into Thalassemia, Sickle Cell Disease and Others. The thalassemia segment acquired the highest revenue share in the hemoglobinopathies market in 2021. It is because thalassemia is a type of blood disorder that is caused by the alteration in the gene. There are two primary types of thalassemia. One is alpha thalassemia which occurs when the alpha globin protein gene or genes are missing or mutated. And the other one is Beta thalassemia which is due to the change in the production of beta globin protein.

Distribution Channel Outlook

By Distribution channel, the is classified into Hospital Pharmacy, Online Providers and Drug Stores and Retail Pharmacy. The Hospital pharmacy segment recorded a significant revenue share in the hemoglobinopathies market in 2021. Due to the composition of the healthcare services, which includes the practice, preparing, compounding, storing, dispensing medicines and medical devices, and patient counseling. Also, they have healthcare professionals like doctors and nurses for effective, safe, and efficient use. In health facilities, a hospital pharmacy is a specialized field of pharmacy which is a part of the patient's health care.

Therapy Outlook

On the basis of Therapy, the hemoglobinopathy market is divided into Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea and Others. The Monoclonal Antibody Medication segment procured the largest revenue share in the hemoglobinopathy market in 2021. It is because of the sufficient medications available for the therapy and also because thalassemia patients show healthy recovery by monoclonal antibody medication. Monoclonal antibodies are similar to antibodies that a human body develops, which mimic the activity of the immune system. They are created through a process in which specific antibodies are drawn out of the blood and then cloned.

Regional Outlook

Region-wise, the hemoglobinopathies market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the largest revenue share in the hemoglobinopathies market in 2021. Due to the awareness programs initiated by the different organizations in which they spread awareness about the diseases related to hemoglobinopathy and the need to research and find new therapies for its treatment. Also, the rising immigration to the region from areas where this disease is widely found and the availability of new and enhanced medications are expected to fuel the market growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.

Scope of the Study

Market Segments covered in the Report:

By Type

• Thalassemia
• Sickle Cell Disease
• Others

By Distribution Channel

• Drug Stores & Retail Pharmacy
• Hospital Pharmacy
• Online Providers

By Therapy

• Monoclonal Antibody Medication
• Hydroxyurea
• ACE Inhibitors
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Abbott Laboratories
• Sanofi S.A.
• Danaher Corporation
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Alnylam Pharmaceuticals, Inc.
• Emmaus Life Sciences, Inc.
• Biogen, Inc.
• Canthera Discovery Ltd.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Hemoglobinopathies Market, by Type
  • 1.4.2 Global Hemoglobinopathies Market, by Distribution Channel
  • 1.4.3 Global Hemoglobinopathies Market, by Therapy
  • 1.4.4 Global Hemoglobinopathies Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market Overview

• 2.1 Introduction
  • 2.1.1 Overview
    • 2.1.1.1 Market composition and Scenarios
• 2.2 Key Factors Impacting the Market
  • 2.2.1 Market Drivers
  • 2.2.2 Market Restraints

Chapter 3. Global Hemoglobinopathies Market by Type

• 3.1 Global Thalassemia Market by Region
• 3.2 Global Sickle Cell Disease Market by Region
• 3.3 Global Others Market by Region

Chapter 4. Global Hemoglobinopathies Market by Distribution Channel

• 4.1 Global Drug Stores & Retail Pharmacy Market by Region
• 4.2 Global Hospital Pharmacy Market by Region
• 4.3 Global Online Providers Market by Region

Chapter 5. Global Hemoglobinopathies Market by Therapy

• 5.1 Global Monoclonal Antibody Medication Market by Region
• 5.2 Global Hydroxyurea Market by Region
• 5.3 Global ACE Inhibitors Market by Region
• 5.4 Global Others Market by Region

Chapter 6. Global Hemoglobinopathies Market by Region

• 6.1 North America Hemoglobinopathies Market
  • 6.1.1 North America Hemoglobinopathies Market by Type
    • 6.1.1.1 North America Thalassemia Market by Country
    • 6.1.1.2 North America Sickle Cell Disease Market by Country
    • 6.1.1.3 North America Others Market by Country
  • 6.1.2 North America Hemoglobinopathies Market by Distribution Channel
    • 6.1.2.1 North America Drug Stores & Retail Pharmacy Market by Country
    • 6.1.2.2 North America Hospital Pharmacy Market by Country
    • 6.1.2.3 North America Online Providers Market by Country
  • 6.1.3 North America Hemoglobinopathies Market by Therapy
    • 6.1.3.1 North America Monoclonal Antibody Medication Market by Country
    • 6.1.3.2 North America Hydroxyurea Market by Country
    • 6.1.3.3 North America ACE Inhibitors Market by Country
    • 6.1.3.4 North America Others Market by Country
  • 6.1.4 North America Hemoglobinopathies Market by Country
    • 6.1.4.1 US Hemoglobinopathies Market
      • 6.1.4.1.1 US Hemoglobinopathies Market by Type
      • 6.1.4.1.2 US Hemoglobinopathies Market by Distribution Channel
      • 6.1.4.1.3 US Hemoglobinopathies Market by Therapy
    • 6.1.4.2 Canada Hemoglobinopathies Market
      • 6.1.4.2.1 Canada Hemoglobinopathies Market by Type
      • 6.1.4.2.2 Canada Hemoglobinopathies Market by Distribution Channel
      • 6.1.4.2.3 Canada Hemoglobinopathies Market by Therapy
    • 6.1.4.3 Mexico Hemoglobinopathies Market
      • 6.1.4.3.1 Mexico Hemoglobinopathies Market by Type
      • 6.1.4.3.2 Mexico Hemoglobinopathies Market by Distribution Channel
      • 6.1.4.3.3 Mexico Hemoglobinopathies Market by Therapy
    • 6.1.4.4 Rest of North America Hemoglobinopathies Market
      • 6.1.4.4.1 Rest of North America Hemoglobinopathies Market by Type
      • 6.1.4.4.2 Rest of North America Hemoglobinopathies Market by Distribution Channel
      • 6.1.4.4.3 Rest of North America Hemoglobinopathies Market by Therapy
• 6.2 Europe Hemoglobinopathies Market
  • 6.2.1 Europe Hemoglobinopathies Market by Type
    • 6.2.1.1 Europe Thalassemia Market by Country
    • 6.2.1.2 Europe Sickle Cell Disease Market by Country
    • 6.2.1.3 Europe Others Market by Country
  • 6.2.2 Europe Hemoglobinopathies Market by Distribution Channel
    • 6.2.2.1 Europe Drug Stores & Retail Pharmacy Market by Country
    • 6.2.2.2 Europe Hospital Pharmacy Market by Country
    • 6.2.2.3 Europe Online Providers Market by Country
  • 6.2.3 Europe Hemoglobinopathies Market by Therapy
    • 6.2.3.1 Europe Monoclonal Antibody Medication Market by Country
    • 6.2.3.2 Europe Hydroxyurea Market by Country
    • 6.2.3.3 Europe ACE Inhibitors Market by Country
    • 6.2.3.4 Europe Others Market by Country
  • 6.2.4 Europe Hemoglobinopathies Market by Country
    • 6.2.4.1 Germany Hemoglobinopathies Market
      • 6.2.4.1.1 Germany Hemoglobinopathies Market by Type
      • 6.2.4.1.2 Germany Hemoglobinopathies Market by Distribution Channel
      • 6.2.4.1.3 Germany Hemoglobinopathies Market by Therapy
    • 6.2.4.2 UK Hemoglobinopathies Market
      • 6.2.4.2.1 UK Hemoglobinopathies Market by Type
      • 6.2.4.2.2 UK Hemoglobinopathies Market by Distribution Channel
      • 6.2.4.2.3 UK Hemoglobinopathies Market by Therapy
    • 6.2.4.3 France Hemoglobinopathies Market
      • 6.2.4.3.1 France Hemoglobinopathies Market by Type
      • 6.2.4.3.2 France Hemoglobinopathies Market by Distribution Channel
      • 6.2.4.3.3 France Hemoglobinopathies Market by Therapy
    • 6.2.4.4 Russia Hemoglobinopathies Market
      • 6.2.4.4.1 Russia Hemoglobinopathies Market by Type
      • 6.2.4.4.2 Russia Hemoglobinopathies Market by Distribution Channel
      • 6.2.4.4.3 Russia Hemoglobinopathies Market by Therapy
    • 6.2.4.5 Spain Hemoglobinopathies Market
      • 6.2.4.5.1 Spain Hemoglobinopathies Market by Type
      • 6.2.4.5.2 Spain Hemoglobinopathies Market by Distribution Channel
      • 6.2.4.5.3 Spain Hemoglobinopathies Market by Therapy
    • 6.2.4.6 Italy Hemoglobinopathies Market
      • 6.2.4.6.1 Italy Hemoglobinopathies Market by Type
      • 6.2.4.6.2 Italy Hemoglobinopathies Market by Distribution Channel
      • 6.2.4.6.3 Italy Hemoglobinopathies Market by Therapy
    • 6.2.4.7 Rest of Europe Hemoglobinopathies Market
      • 6.2.4.7.1 Rest of Europe Hemoglobinopathies Market by Type
      • 6.2.4.7.2 Rest of Europe Hemoglobinopathies Market by Distribution Channel
      • 6.2.4.7.3 Rest of Europe Hemoglobinopathies Market by Therapy
• 6.3 Asia Pacific Hemoglobinopathies Market
  • 6.3.1 Asia Pacific Hemoglobinopathies Market by Type
    • 6.3.1.1 Asia Pacific Thalassemia Market by Country
    • 6.3.1.2 Asia Pacific Sickle Cell Disease Market by Country
    • 6.3.1.3 Asia Pacific Others Market by Country
  • 6.3.2 Asia Pacific Hemoglobinopathies Market by Distribution Channel
    • 6.3.2.1 Asia Pacific Drug Stores & Retail Pharmacy Market by Country
    • 6.3.2.2 Asia Pacific Hospital Pharmacy Market by Country
    • 6.3.2.3 Asia Pacific Online Providers Market by Country
  • 6.3.3 Asia Pacific Hemoglobinopathies Market by Therapy
    • 6.3.3.1 Asia Pacific Monoclonal Antibody Medication Market by Country
    • 6.3.3.2 Asia Pacific Hydroxyurea Market by Country
    • 6.3.3.3 Asia Pacific ACE Inhibitors Market by Country
    • 6.3.3.4 Asia Pacific Others Market by Country
  • 6.3.4 Asia Pacific Hemoglobinopathies Market by Country
    • 6.3.4.1 China Hemoglobinopathies Market
      • 6.3.4.1.1 China Hemoglobinopathies Market by Type
      • 6.3.4.1.2 China Hemoglobinopathies Market by Distribution Channel
      • 6.3.4.1.3 China Hemoglobinopathies Market by Therapy
    • 6.3.4.2 Japan Hemoglobinopathies Market
      • 6.3.4.2.1 Japan Hemoglobinopathies Market by Type
      • 6.3.4.2.2 Japan Hemoglobinopathies Market by Distribution Channel
      • 6.3.4.2.3 Japan Hemoglobinopathies Market by Therapy
    • 6.3.4.3 India Hemoglobinopathies Market
      • 6.3.4.3.1 India Hemoglobinopathies Market by Type
      • 6.3.4.3.2 India Hemoglobinopathies Market by Distribution Channel
      • 6.3.4.3.3 India Hemoglobinopathies Market by Therapy
    • 6.3.4.4 South Korea Hemoglobinopathies Market
      • 6.3.4.4.1 South Korea Hemoglobinopathies Market by Type
      • 6.3.4.4.2 South Korea Hemoglobinopathies Market by Distribution Channel
      • 6.3.4.4.3 South Korea Hemoglobinopathies Market by Therapy
    • 6.3.4.5 Singapore Hemoglobinopathies Market
      • 6.3.4.5.1 Singapore Hemoglobinopathies Market by Type
      • 6.3.4.5.2 Singapore Hemoglobinopathies Market by Distribution Channel
      • 6.3.4.5.3 Singapore Hemoglobinopathies Market by Therapy
    • 6.3.4.6 Malaysia Hemoglobinopathies Market
      • 6.3.4.6.1 Malaysia Hemoglobinopathies Market by Type
      • 6.3.4.6.2 Malaysia Hemoglobinopathies Market by Distribution Channel
      • 6.3.4.6.3 Malaysia Hemoglobinopathies Market by Therapy
    • 6.3.4.7 Rest of Asia Pacific Hemoglobinopathies Market
      • 6.3.4.7.1 Rest of Asia Pacific Hemoglobinopathies Market by Type
      • 6.3.4.7.2 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel
      • 6.3.4.7.3 Rest of Asia Pacific Hemoglobinopathies Market by Therapy
• 6.4 LAMEA Hemoglobinopathies Market
  • 6.4.1 LAMEA Hemoglobinopathies Market by Type
    • 6.4.1.1 LAMEA Thalassemia Market by Country
    • 6.4.1.2 LAMEA Sickle Cell Disease Market by Country
    • 6.4.1.3 LAMEA Others Market by Country
  • 6.4.2 LAMEA Hemoglobinopathies Market by Distribution Channel
    • 6.4.2.1 LAMEA Drug Stores & Retail Pharmacy Market by Country
    • 6.4.2.2 LAMEA Hospital Pharmacy Market by Country
    • 6.4.2.3 LAMEA Online Providers Market by Country
  • 6.4.3 LAMEA Hemoglobinopathies Market by Therapy
    • 6.4.3.1 LAMEA Monoclonal Antibody Medication Market by Country
    • 6.4.3.2 LAMEA Hydroxyurea Market by Country
    • 6.4.3.3 LAMEA ACE Inhibitors Market by Country
    • 6.4.3.4 LAMEA Others Market by Country
  • 6.4.4 LAMEA Hemoglobinopathies Market by Country
    • 6.4.4.1 Brazil Hemoglobinopathies Market
      • 6.4.4.1.1 Brazil Hemoglobinopathies Market by Type
      • 6.4.4.1.2 Brazil Hemoglobinopathies Market by Distribution Channel
      • 6.4.4.1.3 Brazil Hemoglobinopathies Market by Therapy
    • 6.4.4.2 Argentina Hemoglobinopathies Market
      • 6.4.4.2.1 Argentina Hemoglobinopathies Market by Type
      • 6.4.4.2.2 Argentina Hemoglobinopathies Market by Distribution Channel
      • 6.4.4.2.3 Argentina Hemoglobinopathies Market by Therapy
    • 6.4.4.3 UAE Hemoglobinopathies Market
      • 6.4.4.3.1 UAE Hemoglobinopathies Market by Type
      • 6.4.4.3.2 UAE Hemoglobinopathies Market by Distribution Channel
      • 6.4.4.3.3 UAE Hemoglobinopathies Market by Therapy
    • 6.4.4.4 Saudi Arabia Hemoglobinopathies Market
      • 6.4.4.4.1 Saudi Arabia Hemoglobinopathies Market by Type
      • 6.4.4.4.2 Saudi Arabia Hemoglobinopathies Market by Distribution Channel
      • 6.4.4.4.3 Saudi Arabia Hemoglobinopathies Market by Therapy
    • 6.4.4.5 South Africa Hemoglobinopathies Market
      • 6.4.4.5.1 South Africa Hemoglobinopathies Market by Type
      • 6.4.4.5.2 South Africa Hemoglobinopathies Market by Distribution Channel
      • 6.4.4.5.3 South Africa Hemoglobinopathies Market by Therapy
    • 6.4.4.6 Nigeria Hemoglobinopathies Market
      • 6.4.4.6.1 Nigeria Hemoglobinopathies Market by Type
      • 6.4.4.6.2 Nigeria Hemoglobinopathies Market by Distribution Channel
      • 6.4.4.6.3 Nigeria Hemoglobinopathies Market by Therapy
    • 6.4.4.7 Rest of LAMEA Hemoglobinopathies Market
      • 6.4.4.7.1 Rest of LAMEA Hemoglobinopathies Market by Type
      • 6.4.4.7.2 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel
      • 6.4.4.7.3 Rest of LAMEA Hemoglobinopathies Market by Therapy

Chapter 7. Company Profiles

• 7.1 Abbott Laboratories
  • 7.1.1 Company Overview
  • 7.1.2 Financial Analysis
  • 7.1.3 Segmental and Regional Analysis
  • 7.1.4 Research & Development Expense
  • 7.1.5 SWOT Analysis
• 7.2 Sanofi S.A.
  • 7.2.1 Company Overview
  • 7.2.2 Financial Analysis
  • 7.2.3 Segmental and Regional Analysis
  • 7.2.4 Research & Development Expense
  • 7.2.5 Recent strategies and developments:
    • 7.2.5.1 Trials and Approvals:
• 7.3 Danaher Corporation
  • 7.3.1 Company Overview
  • 7.3.2 Financial Analysis
  • 7.3.3 Segmental and Regional Analysis
  • 7.3.4 Research & Development Expense
• 7.4 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
  • 7.4.1 Company Overview
  • 7.4.2 Financial Analysis
  • 7.4.3 Regional & Segmental Analysis
  • 7.4.4 Research & Development Expense
  • 7.4.5 Recent strategies and developments:
    • 7.4.5.1 Partnerships, Collaborations, and Agreements:
    • 7.4.5.2 Approvals and Trials:
• 7.5 Merck & Co., Inc.
  • 7.5.1 Company Overview
  • 7.5.2 Financial Analysis
  • 7.5.3 Segmental and Regional Analysis
  • 7.5.4 Research & Development Expenses
• 7.6 Bristol Myers Squibb Company
  • 7.6.1 Company Overview
  • 7.6.2 Financial Analysis
  • 7.6.3 Regional Analysis
  • 7.6.4 Research & Development Expenses
• 7.7 Alnylam Pharmaceuticals, Inc.
  • 7.7.1 Company Overview
  • 7.7.2 Financial Analysis
  • 7.7.3 Research & Development Expense
• 7.8 Emmaus Life Sciences, Inc.
  • 7.8.1 Company Overview
  • 7.8.2 Financial Analysis
  • 7.8.3 Research & Development Expenses
• 7.9 Biogen, Inc.
  • 7.9.1 Company Overview
  • 7.9.2 Financial Analysis
  • 7.9.3 Regional Analysis
  • 7.9.4 Research & Development Expense
• 7.10. Canthera Discovery Ltd.
  • 7.10.1 Company Overview